Author(s):
Pragati R. Kamble, Nikita V. Pandagale, Omkar D. Ghatage, Pramod B. Patil, S. V. Patil
Email(s):
pragatikamble7001@gmail.com , nikitavpandagale0297@gmail.com , ghatageomkar4041@gmail.com
DOI:
10.52711/2231-5675.2023.00002 
Address:
Pragati R. Kamble1*, Nikita V. Pandagale2, Omkar D. Ghatage3, Pramod B. Patil4, S. V. Patil5
1,2,3Department of Pharmaceutical Quality Assurance, Ashokrao Mane College of Pharmacy, Pethvadgaon, Kolhapur - 416112, Maharashtra, India.
4Department of Pharmaceutical Chemistry, Ashokrao Mane College of Pharmacy, Pethvadgaon, Kolhapur - 416112, Maharashtra, India.
5Department of Pharmaceutics, Ashokrao Mane College of Pharmacy, Pethvadgaon, Kolhapur - 416112, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 1,
Year - 2023
ABSTRACT:
A new accurate, specific, precise, high performance liquid chromatographic (HPLC) method has been developed and validated for the determination of Febuxostat in bulk and in its pharmaceutical dosage forms of tablet. Acetonitrile: Methanol (70:30) was used as the mobile phase at a flow rate of 1.0ml/min using a Symmetry C18 column Finepack SIL C18T-5 (250x4.6mm, 5m). The effluent was spectroscopically monitored at 314nm. The intraday and inter-day precisions showed coefficients of variation ranged from 0.62% to 2.78% at different levels of concentrations. The calibration curve was linear with a correlation coefficient of 0.9947. The averages of the absolute and relative recoveries were found to be 98.67% to 98.96%. The proposed HPLC method was successfully applied to quantify the amount of Febuxostat in bulk and dosage forms in quality control.
Cite this article:
Pragati R. Kamble, Nikita V. Pandagale, Omkar D. Ghatage, Pramod B. Patil, S. V. Patil. Development and Validation of RP-HPLC Method for Determination of Febuxostat in Bulk and Pharmaceutical Dosage Formulations. Asian Journal of Pharmaceutical Analysis. 2023; 13(1):7-2. doi: 10.52711/2231-5675.2023.00002
Cite(Electronic):
Pragati R. Kamble, Nikita V. Pandagale, Omkar D. Ghatage, Pramod B. Patil, S. V. Patil. Development and Validation of RP-HPLC Method for Determination of Febuxostat in Bulk and Pharmaceutical Dosage Formulations. Asian Journal of Pharmaceutical Analysis. 2023; 13(1):7-2. doi: 10.52711/2231-5675.2023.00002 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2023-13-1-2
REFERENCES:
1. Jack Cazes, Encyclopedia of Chromatography, 2004, Updated supplement, Pages- 330.
2. Robert E. Andrey, Liquid Chromatography-Mass Spectrometry: An Introduction, Pages-7.
3. A.H. Buckett, J.B. Stenlake, Practical Pharmaceutical Chemistry, 4th edition, Part- II, Pages-165-166.
4. Monika Bakshi, Saranjit Singh, J. Pharmaceutical And Biomedical Analysis, Vol- 28, 2002, Page No. 1011.
5. Susan P. B, Febuxostat; A selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. The Annals of Pharmacotherapy. 2006; 40: 2187-2194.
6. Charnelda L.G, NafesaE, Walters-Smith. Febuxostat for treatment of chronic gout. American Journal of Health-System Pharmacy. 2011; 68(5): 389-398.
7. Ramallo I.A, Susana A.Z, Ricardo L.E.F. A rapid TLC autographic method for the detection of xanthine oxidase inhibitors and superoxide scavengers. Phytochemical Analysis, 2006; 17(1): 15-19.
8. Grabowski B. A, Khosravan R, Vernillet L, Mulford D. J, Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects, Journal of Clinical Pharmacology, 2011; 51(2): 2011.
9. Khosravan R., Grabowski B, Wu J.T, Joseph-Ridge N, Vernillet L, Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects, British Journal of Clinical Pharmacology, 2008; 65(3): 355-363.
10. Love B.L, Barrons R, Veverka A, Snider K.M. Urate-lowering therapy for gout: focus on febuxostat. Pharmacotherapy.2010; 30:594-608.